Eisai’s LEADER study reported that 83% of early Alzheimer’s patients were stable or improved on Leqembi. Here is what a retrospective abstract can establish.
Real World Study Tracked Lecanemab Outcomes Three Years After Approval Across Diverse United States Clinical Settings
by | Jul 28, 2026 | Uncategorized | 0 comments
Recent Comments